Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

OTHER 24INDUSTRY 6NIH 4NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Precancerous Conditions 1Colorectal Neoplasms 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Interventional × Eflornithine × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT00983580 2019-09-04

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
107 enrolled 10 charts

Adenomatous Polyps

NCT00118365 2015-01-22

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

National Cancer Institute (NCI)

Phase 3 Completed
375 enrolled 27 charts
Other neoplasm

Precancerous Conditions

NCT00003814 2013-12-18

Eflornithine in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
450 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡